+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients



Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients



European Journal of Neurology 20(7): 1060-1067



It is still unclear which patients benefit more from available disease-modifying treatments (DMTs) in multiple sclerosis (MS). Our objective is to identify the baseline clinical and magnetic resonance imaging (MRI) predictors of response to first-line DMTs in a cohort of relapsing-remitting (RR) MS patients in a real-world clinical setting. Consecutive naïve RRMS patients treated with interferon-beta or glatiramer acetate have been included and followed for 2 years. Patients were grouped into responders (R) in case of absence of clinical and MRI activity, and non-responders (NR) if the on-treatment annualized relapse rate (ARR) reduction was < 50% of the ARR in the 2 years before treatment or in the presence of MRI activity (≥ 2 active lesions at 1-year MRI or ≥ 4 active lesions at 1 + 2-year MRI). At 2-year follow-up, 272 patients were R (34.6%) and 322 NR (40.9%), and multivariate analysis revealed that a later age at onset of the disease (P < 0.0001), a lower disability (P < 0.0001) and a lower number of gadolinium-enhancing lesions at baseline MRI (P = 0.002) were predictors of efficacy of DMTs. Moreover, the first year response had a good predictive power on the second year, as 73.7% of 1-year R had no evidence of clinical and MRI activity within the ensuing year. A lower baseline MRI and clinical activity have been identified as predictors of DMT efficacy in patients with RRMS in routine clinical practice. Evaluation of clinical and MRI activity at 1 year is recommended to monitor patients over time.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052104766

Download citation: RISBibTeXText

PMID: 23425504

DOI: 10.1111/ene.12119


Related references

Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis. Neurologia 24(7): 435-438, 2009

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Multiple Sclerosis 21(9): 1159-1171, 2015

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet. Neurology 7(10): 903-914, 2008

Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study. Journal of Medical Economics 17(3): 215-222, 2014

Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Journal of Medical Economics 19(7): 684-695, 2016

Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. International Journal of Ms Care 18(3): 138-146, 2016

Cost Analysis of the Use of Glatiramer Acetate Compared to Interferon-Â in Patients with Relapsing-Remitting Multiple Sclerosis and Spasticity in Spain. Value in Health 17(7): A394, 2014

Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study. Journal of the Neurological Sciences 315(1-2): 123-128, 2012

Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial. Clinical Neurology and Neurosurgery 160: 69-72, 2017

Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. Multiple Sclerosis 20(12): 1602-1608, 2014

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Health Economics Review 5(1): 30, 2015

Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. Clinical Therapeutics 32(6): 1061-1066, 2010

Onset of clinical benefit of glatiramer acetate in 255 patients with relapsing remitting multiple sclerosis. Neurology 60(5 Suppl. 1): A480, 2003

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet. Neurology 8(10): 889-897, 2009

Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry 86(9): 1016-1020, 2015